ABIVAX stood out with one of the strongest weekly gains in the Parisian market, showing notable progress while the main French stock indices trended downwards. The volatility of the stock was sensitive, accompanying a dynamic sequence within an overall environment of declining index values. This development is part of an already exceptional year for the company.
At the end of the week, ABIVAX's stock closed at €90.90, up 14.63% over five sessions. Over the past twelve months, the stock has soared by 832.30%, positioning ABIVAX among the strongest growths in the Parisian market during this period. This movement occurs in a general context marked by a correction of the major French indices: the CAC 40 fell by 1.27% over the same week, while the SBF 120 reported a loss of 1.30%. Compared to these indices, ABIVAX's outperformance is all the more striking. The stock is also trading at historically high levels, having reached an annual low of €4.51 and a high of €85.40. This weekly dynamic is accompanied by sustained trading, suggesting a constant interest from operators in the stock.
Technical Analysis and Market Position
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
From a technical standpoint, ABIVAX is positioned above its main reference levels. The closing price of €90.90 corresponds to the identified resistance zone, well above its medium and long-term moving averages: the 50-day moving average is at €74.71 and the 200-day moving average at €29.53. The stock also deviates from its Bollinger bands, trading beyond the upper band set at €89.09, while the lower band is at €72.31. In terms of trend indicators, the RSI is at 67, signaling a robust movement, and the MACD line, positive at 3.45, confirms the bullish momentum recorded. The one-month volatility, at 13.81, attests to a significant amplitude of variation over this period. Finally, the stock maintains a support threshold identified around €69.40, a level beyond which it has not receded during the recent period.
Trésorerie et équivalents de trésorerie de 589,7 millions d'euros au 30/09/2025 ; perte nette de 254,1 millions d'euros sur les neuf mois ; produit net d'ADS d'environ 700,3 millions de dollars (?597,2 M€) en juillet 2025 ; position financière nette de 543,3 millions d'euros ; autonomie financière attendue jusqu'au T4 2027. Hausse significative des dépenses R&D et des charges G&A.
Risks mentioned
Risques inhérents à la recherche et au développement clinique
Risque lié aux décisions des autorités réglementaires (FDA, EMA)
Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)
Opportunities identified
Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
